G17 neutralization studies with CDR-derived peptidomimetics in comparison with anti-G17 scFvs and mAbs. A and C, G17-neutralizing activities of 189DB3-derived bicyclic mimetics 1d/1h, tricyclic mimetics 2a/2b, monocyclic mimetics 3a/3b, cyclic T3-less mimetic 4a, and linear mimetic 5 at five different concentrations (200–12.5 μm) using Gonadotropin-releasing hormone-derived bicyclic peptidomimetic 1x (−4 charge) as negative control. B and D, G17 neutralizing activities of anti-G17 scFv and mAbs at five different concentrations (1.6–0.1 μm) using anti-GST mAb as negative control. G17 neutralization studies BxPc3 (A and B) and Colo320 WT cell-based bioassays (C and D). Media and standard deviation of the assays are represented in the figure. B and D, data were adapted from Refs. 35, 36.